Arcellx

ACLX

Market cap $4.17B

Overview Fund Activity

75.20 USD

-0.99

1.3%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

75.20

0.00

0%

1 day

-1.3%

5 days

5.75%

1 month

1.51%

3 months

17.33%

6 months

3.38%

Year to date

-4.51%

1 year

-2.35%

5 years

347.62%

10 years

347.62%

About: Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Employees: 163

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

3% more funds holding

Funds holding: 195 [Q1] → 201 (+6) [Q2]

0.67% less ownership

Funds ownership: 112.07% [Q1] → 111.39% (-0.67%) [Q2]

1% less capital invested

Capital invested by funds: $4.04B [Q1] → $4.01B (-$31.8M) [Q2]

14% less funds holding in top 10

Funds holding in top 10: 14 [Q1] → 12 (-2) [Q2]

26% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 82

68% less call options, than puts

Call options by funds: $18.7M | Put options by funds: $58.5M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$110

46% upside

Avg. target

$119

59% upside

High target

$133

77% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Scotiabank George Farmer	$133	Sector Outperform Maintained	31 Jul 2025
Citigroup Geoff Meacham	$110	Buy Initiated	17 Jun 2025
HC Wainwright & Co. Emily Bodnar	$115	Buy Reiterated	16 Jun 2025

See Analyst Rankings

Financial journalist opinion

Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arcellx, Inc. (NASDAQ:ACLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Rami Elghandour - Chairman of the Board, CEO & President Christopher Heery - Chief Medical Officer Michelle Gilson - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Good afternoon, everyone. Welcome to the session of the Morgan Salary Global Healthcare Conference.

Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 2025 Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025 at 1:05 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in.

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robust pipeline, and potential to triple revenues by 2030.

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

Zacks Investment Research

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $0.51 per share a year ago.

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

The Motley Fool

Arcellx (ACLX) Q2 Revenue Drops 72%

Arcellx (ACLX) Q2 Revenue Drops 72%

Arcellx (ACLX) Q2 Revenue Drops 72%

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registrational iMMagine-1 study continue to demonstrate anito-cel's potential to be a life-changing therapy for mu.

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

Arcellx, Inc. is advancing its lead CAR-T therapy, anito-cel, for relapsed/refractory multiple myeloma, with the pivotal phase 3 iMMagine-3 trial underway. Recent positive phase 2 iMMagine-1 data support the potential of anito-cel, especially in 2nd-line+ multiple myeloma patients who failed prior therapies. The FDA has allowed a dual primary endpoint—progression-free survival and MRD-negativity—in the ongoing phase 3 iMMagine-3 study, enhancing regulatory prospects.

Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

Investors Business Daily

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at.

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma$

See News Rankings

Charts implemented using Lightweight Charts™